Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics to Present at Two Upcoming March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: The 38th Annual Cowen & Co. Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA. Oppenheimer's 28th Annual Healthcare Conference: a corporate overview wil... 
Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
- Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phase 1b study data obtained for SER-262, the first ever rationally-designed fermented microbiome therapeutic candidate evaluated in humans– - Collaboration with MD Anderson and Parker Institute intends to initiate clinical study in 2018 to evaluate microbiome therapeutic... 
Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5092388. To joi... 
Download DocumentationCorporate Presentation

Prior to
03/20/18 10:20 a.m. ET
Seres Therapeutics, Inc. at Oppenheimer's 28th Annual Healthcare Conference
Enter your e-mail address 
Stock Quote
 + 0.02 (0.00%)
03/16/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.